ArQule Inc (ARQL)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:ArQule Inc (ARQL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012283
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ArQule Inc (ArQule) is a development stage clinical biotechnology company. It carries out discovery and development of next-generation, small molecule therapeutics for the treatment of various types of cancer. ArQule develops its oncology product candidates through novel approaches including activated checkpoint therapy platform and c-met survival protein platform. Its lead product candidate, ARQ 197 (tivantinib), an inhibitor of the c-Met receptor tyrosine kinase, is undergoing clinical-stage development. The other product pipeline of the company includes ARQ 087 is a multi-kinase inhibitor, ARQ 092 is an Akt inhibitor, ARQ 751 is a next-generation inhibitor of Akt, ARQ 761 is an activator of the damage response pathway, , ARQ 531 is a B-cell malignancies and ARQ 087 is an inhibitor of fibroblast growth factor receptor. ArQule is headquartered in Burlington, Massachusetts, the US.

ArQule Inc (ARQL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
ArQule Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
ArQule Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ArQule Inc, Pharmaceuticals & Healthcare, Deal Details 11
Private Equity 11
ArQule Raises USD15.7 Million in Private Placement of Common Stock 11
Partnerships 12
ArQule Enters into Co-Development Agreement with National Human Genome Research Institute for ARQ 092 12
Licensing Agreements 13
Daiichi Sankyo Exercises Option To Obtain License For ARQ 092 From ArQule 13
Equity Offering 15
ArQule to Raise Funds in Secondary Offering of Shares 15
ArQule Raises USD9.5 Million in Private Placement of Preferred Shares and Warrants 16
ArQule to Raise Up to USD30 Million in Issue of Shares 17
ArQule Raises USD15.3 Million in Private Placement of Shares 18
ArQule Completes Public Offering Of Common Stock For US$60 Million 19
ArQule Completes An Underwritten Public Offering Of Its Common Stock For US$49.51 Million 21
ArQule Inc – Key Competitors 23
ArQule Inc – Key Employees 24
ArQule Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Financial Announcements 26
Nov 09, 2017: ArQule Reports Third Quarter 2017 Financial Results 26
Aug 04, 2017: ArQule Reports Second Quarter 2017 Financial Results 28
May 03, 2017: Arqule Reports First Quarter 2017 Financial Results 29
Mar 07, 2017: ArQule Reports Fourth Quarter and Full Year 2016 Financial Results 30
Nov 07, 2016: ArQule Reports Third Quarter 2016 Financial Results 32
Aug 03, 2016: ArQule Reports Second Quarter 2016 Financial Results 34
May 04, 2016: ArQule Reports First Quarter 2016 Financial Results 36
Feb 29, 2016: ArQule Reports Fourth Quarter and Full Year 2015 Financial Results 38
Product News 40
06/30/2016: ArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer 40
06/23/2016: ArQule to Present Preliminary Phase 1/2 Data for FGFR Inhibitor, ARQ 087, in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer 41
06/07/2017: ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases 42
06/03/2017: ArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology Annual Meeting 43
05/17/2017: ArQule to Present Clinical Data on ARQ-087 at the 2017 American Society of Clinical Oncology Annual Meeting 44
Product Approvals 45
Nov 01, 2017: FDA Grants Rare Pediatric Disease Designation to ArQule’s Miransertib (ARQ 092) for the Treatment of Proteus Syndrome 45
Clinical Trials 46
Nov 21, 2017: ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocarcinoma 46
Jul 11, 2017: ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies 47
Jun 23, 2017: ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association 48
May 18, 2017: ArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association 49
May 17, 2017: ArQule to Present Clinical Data on ARQ-092 at the 2017 American Society of Clinical Oncology Annual Meeting 50
May 17, 2017: ArQule to Present Clinical Data on ARQ-761 at the 2017 American Society of Clinical Oncology Annual Meeting 51
Apr 11, 2017: ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531 52
Dec 04, 2016: Data on Proprietary BTK Inhibitor, ARQ 531, Demonstrating Inhibition of Wild Type and C481S Mutant BTK and Superiority to Ibrutinib in TCL1 Mouse Model Presented at the American Society of Hematology Annual Meeting 53
Dec 03, 2016: Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at the American Society of Hematology Annual Meeting 54
Sep 15, 2016: ArQule Announces Publication of Manuscript Highlighting Preclinical Activity of FGFR Inhibitor, ARQ 087, in Peer Reviewed Journal 55
Jul 18, 2016: ArQule Presents Preclinical Data for ARQ 531, a Proprietary Reversible Inhibitor of Wild Type and Mutant BTK, at the 2016 Pan Pacific Lymphoma Conference 56
Mar 22, 2016: Daiichi Sankyo and ArQule Announce Continuation of METIV-HCC Phase 3 Study of Tivantinib in Second-Line Hepatocellular Carcinoma 57
Jan 28, 2016: ArQule Provides Update on ARQ 092 58
Jan 28, 2016: ArQule Provides Update on ARQ 751 59
Jan 25, 2016: ArQule Presents Clinical Biomarker Data From Phase 2 Study and Ongoing Phase 3 METIV-HCC Study of Tivantinib in Second-Line Hepatocellular Carcinoma at the 2016 Gastrointestinal Cancers Symposium 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
ArQule Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
ArQule Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
ArQule Inc, Deals By Therapy Area, 2011 to YTD 2017 9
ArQule Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ArQule Raises USD15.7 Million in Private Placement of Common Stock 11
ArQule Enters into Co-Development Agreement with National Human Genome Research Institute for ARQ 092 12
Daiichi Sankyo Exercises Option To Obtain License For ARQ 092 From ArQule 13
ArQule to Raise Funds in Secondary Offering of Shares 15
ArQule Raises USD9.5 Million in Private Placement of Preferred Shares and Warrants 16
ArQule to Raise Up to USD30 Million in Issue of Shares 17
ArQule Raises USD15.3 Million in Private Placement of Shares 18
ArQule Completes Public Offering Of Common Stock For US$60 Million 19
ArQule Completes An Underwritten Public Offering Of Its Common Stock For US$49.51 Million 21
ArQule Inc, Key Competitors 23
ArQule Inc, Key Employees 24

★海外企業調査レポート[ArQule Inc (ARQL)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • FHI 360:企業の戦略的SWOT分析
    FHI 360 - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • China Mobile Limited:戦略・SWOT・企業財務分析
    China Mobile Limited - Strategy, SWOT and Corporate Finance Report Summary China Mobile Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • PNM Resources, Inc. (PNM)-エネルギー分野:企業M&A・提携分析
    Summary PNM Resources, Inc. (PNMR) is an investor-owned holding company that provides electricity and electric services in New Mexico and Texas. It has interests in PNM and TNMP utilities. PNM produces electricity from coal, natural gas, nuclear, solar, wind, and geothermal sources; transmits and di …
  • Marathon Petroleum Corporation (MPC)-石油・ガス分野:企業M&A・提携分析
    Summary Marathon Petroleum Corporation (MPC) is a downstream energy company, which refines, markets and transports petroleum products. It owns and operates refineries in the Gulf Coast and Midwest regions of the US. MPC owns common carrier pipeline systems that transport crude oil and refined produc …
  • AOL Inc:企業の戦略的SWOT分析
    AOL Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Swarovski AG:企業の戦略・SWOT・財務分析
    Swarovski AG - Strategy, SWOT and Corporate Finance Report Summary Swarovski AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Meidensha Corporation:企業の戦略・SWOT・財務情報
    Meidensha Corporation - Strategy, SWOT and Corporate Finance Report Summary Meidensha Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Ithaca Energy Inc. (IAE)-石油・ガス分野:企業M&A・提携分析
    Summary Ithaca Energy Inc. (Ithaca) is an oil and gas company, which explores for, develops, and produces oil and gas in the North Sea. It focuses on the appraisal and development of undeveloped discoveries and the exploitation of its existing UK producing asset portfolio. The company has a portfoli …
  • Interpace Diagnostics Group Inc (IDXG)-製薬・医療分野:企業M&A・提携分析
    Summary Interpace Diagnostics Group Inc (Interpace Diagnostics), formerly PDI Inc, is a developer of molecular diagnostics tests. The company offers PancraGen, a DNA based molecular test that aids in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its pathfinder platform; a …
  • Pro-Pac Packaging Ltd (PPG):企業の財務・戦略的SWOT分析
    Pro-Pac Packaging Ltd (PPG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • QPS Austria GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary QPS Austria GmbH (QPS), a subsidiary of QPS Holdings LLC, is a contract research organization (CRO) which provides preclinical and clinical research services. The company offers in vivo services which include generating, characterizing and maintaining transgenic disease models and use them f …
  • i-Optics BV-医療機器分野:企業M&A・提携分析
    Summary i-Optics BV (i-Optics) is a medical device company that manufactures and distributes optical devices. The company provides easyscan, eyeprevent and cassini for age related eye diseases. The company’s cassini is a corneal topography measurement device for contact lens fitting, corneal transpl …
  • Mesa Laboratories Inc (MLAB):企業の財務・戦略的SWOT分析
    Summary Mesa Laboratories Inc (Mesa) is a medical device company that manufactures and markets validation and monitoring instruments. The company’s products include mesa biological indicators, DryCal gas flow calibrators, BGI ambient particulate sampling, DialyGuard dialysate meters, SureTorque cap …
  • Slovensky plynarensky priemysel AS:企業の戦略的SWOT分析
    Slovensky plynarensky priemysel AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • RentPath, LLC:企業の戦略・SWOT・財務分析
    RentPath, LLC - Strategy, SWOT and Corporate Finance Report Summary RentPath, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • MSM Malaysia Holdings Berhad (MSM):企業の財務・戦略的SWOT分析
    MSM Malaysia Holdings Berhad (MSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Greenyard NV:企業の戦略・SWOT・財務分析
    Greenyard NV - Strategy, SWOT and Corporate Finance Report Summary Greenyard NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • FactSet Research Systems Inc. (FDS):企業の財務・戦略的SWOT分析
    FactSet Research Systems Inc. (FDS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Marinus Pharmaceuticals Inc (MRNS):企業の財務・戦略的SWOT分析
    Summary Marinus Pharmaceuticals Inc (Marinus Pharmaceuticals) is a biopharmaceutical company which discovers, develops and commercializes medicines for the treatment of epilepsy and other neuropsychiatric disorders. The company is evaluating its lead product candidate Ganaxolone, a gamma-aminobutyri …
  • Clinigen Group Plc (CLIN):企業の財務・戦略的SWOT分析
    Summary Clinigen Group Plc (Clinigen Group) is a pharmaceutical and services company that provides access to clinical trials, medicines, unlicensed and commercial supply. The company acquires and licenses essential commercial medicines such as foscavir, cardioxane, ethyol, savene and vibativ. It off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆